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Abstract
Background: MicroRNAs are stable and easy to detect in plasma. The plasma levels of microRNAs are often
changed in disease conditions, including cancer. This makes circulating microRNAs a novel class of biomarkers for
cancer diagnosis. Analyses of online microRNA data base revealed that expression level of three microRNAs,
microRNA-24 (miR-24), microRNA-320a (miR-320a), and microRNA-423-5p (miR-423-5p) were down-regulated in
colorectal cancer (CRC). However, whether the plasma level of these three microRNAs can serve as biomarkers for
CRC diagnosis and prognosis is not determined.
Methods: Plasma samples from 223 patients with colorectal related diseases (111 cancer carcinoma, 59 adenoma,
24 colorectal polyps and 29 inflammatory bowel disease) and 130 healthy controls were collected and subjected to
reverse transcription-quantitative real time PCR (RT-qPCR) analyses for the three microRNAs. In addition, plasma
samples from 43 patients were collected before and after surgical treatment for the same RT-qPCR analyses.
Results: The concentrations of plasma miR-24, miR-320a and miR-423-5p were all decreased in patients with CRC
and benign lesions (polyps and adenoma) compared with healthy controls, but increased in inflammatory bowel
disease (IBD). The sensitivity of miR-24, miR-320a and miR-423-5p for early stage of CRC were 77.78 %, 90.74 %, and
88.89 %, respectively. Moreover, the plasma concentration of the three microRNAs was increased in patients after
the surgery who had clinical improvement.
Conclusions: The plasma levels of miR-24, miR-320a, and miR-423-5p have promising potential to serve as novel
biomarkers for CRC detection, especially for early stage of CRC, which are superior to the currently used clinical
biomarkers for CRC detection, such as CEA and CA19-9. Further efforts to develop the three microRNAs as
biomarkers for early CRC diagnosis and prediction of surgical treatment outcomes are warrant.
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Background
Colorectal carcinoma (CRC) is the one of the most com-
mon cancer-related mortalities worldwide [1]. In 2012,
approximately 1,361,000 cases were diagnosed with CRC
and 694,000 patients died of CRC according to the
World Health Organization. Since early detection is
critical for improving outcomes and reducing mortality
of CRC patients, there is an urgent need to identify bio-
markers for early diagnosis and prognosis of the disease.
Currently, CEA and CA19-9 are the most commonly
used circulating biomarkers for gastrointestinal tract
tumor diagnosis [2]. However, the elevation of CEA con-
centration rarely occurs in patients with early stages
CRC [2]. The sensitivity and validity of CEA detection
are also not sufficient for early cancer detection [3]. The
sensitivity of CA19-9 as a cancer biomarker is even less
than that of CEA [4]. Except CEA and CA19-9, there
are few other valuable biomarkers for monitoring CRC.
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Therefore, it is imperative to develop novel sensitive and
specific circulating biomarkers for detection of CRC, es-
pecially in the early stages.
MicroRNAs are small non-coding RNAs of 18–22 nu-
cleotides in length, which regulate gene expression at
the post-transcriptional level by binding to the untrans-
lated regions (UTRs) of mRNAs [5–7]. Since their dis-
covery in 1993, emerging evidence shows that altered
expression of microRNAs is associated with cancer, in-
cluding CRC [1, 8–10]. MicroRNAs can be released to
the blood. Since plasma microRNAs are protected from
RNase digestions, they remain stable for a long period of
time even under extreme harsh conditions. The stability
and easy detectability make circulating microRNAs an
ideal candidate to serve as a biomarker for cancer detec-
tion [11]. In addition, the abundance of plasma micro-
RNAs normally does not vary in different gender [12–17].
Therefore, circulating microRNAs show great potential
values as tumor markers for cancer diagnosis.
It has been reported that miR-24 and miR-320a act
have tumor suppress activity in CRC. MiR-24 inhibits
cell cycle progression via a p53- and p21-independent
manner, and its expression is downregulated in CRC
[18]. MiR-320a suppresses initiation, metastasis, and in-
vasion of CRC [19–21]. In addition, it also induces G0/
G1 arrest in CRC [22]. The expression of miR-320a is in-
versely associated with CRC aggressiveness of CRC and
CRC cell lines [20]. Although expression of miR-423-5p,
miR-24 and miR320a is down-regulated in CRC cell
lines, it remains unknown whether plasma level of the
three microRNA is changed in patients with CRC. To
determine whether the abundance of miR-24, miR-320a,
and miR435-5p in the plasma was changed in CRC pa-
tients and could serve as biomarkers for therapy evalu-
ation, we measured the plasma concentration of miR-24,
miR-320a, and miR435-5p in CRC patients prior or post
the surgery, as well as healthy controls. The results
showed that plasma levels of miR-24, miR-320a, and
miR-423-5p were decreased in patients with CRC, be-
nign lesions (polyps and adenoma) compared with
healthy controls, but increased in patient with inflamma-
tory bowel disease (IBD). The concentration of the three
microRNAs was increased with the clinical improvement
of the patients after the surgery. In addition, the three
microRNAs all showed high detection rates for early
stage of CRC. The results indicate that the plasma levels
of miR-24, miR-320a, and miR-423-5p have the potential
to serve as biomarkers for CRC detection, especially for
early stage of CRC.
Methods
Ethics statement
The study was carried out according to the ethical prin-
ciples of the 2008 revised Declaration of Helsinki. All
plasma-based studies were approved by the Ethics Com-
mittee of the Xiamen University affiliated Zhongshan
Hospital. All participants gave a written consent and
agreed their information to be stored in the hospital
database and used for research purposes.
Plasma sample collection
Blood samples were collected from CRC patients who
had been diagnosed categorized based on the Inter-
national Union Against Cancer (UICC) and American
Joint Committee on Cancer (AJCC) TNM staging system
for CRC established in 2003. Age- and gender-matched
healthy individuals with no history of cancer and in good
health conditions based on self-report were collected
from Xiamen University affiliated Zhongshan Hospital
between December 2012 and November 2013. The IBD
was diagnosed based on standard endoscopic, histologic,
and radiographic criteria. Patients with other gastro-
intestinal tract complications, hemolysis, or high blood
lipid were excluded. The blood samples were collected
from patients before operational treatments, chemother-
apy, or radiotherapy. At 10 days post the operation,
paired plasma samples were collected from 43 randomly
selected patients. All plasma samples were extracted
from EDTA-K2 tubes and centrifuged as described previ-
ously [23]. After the first centrifugation for 10 min at
1,600 g, the supernatants were carefully removed and
transferred to a new tube follow by centrifugation again
at 16,000 g for 10 min to remove residual blood cells.
The plasma was then divided into small aliquots and
snap-frozen at −80 °C. Clinical characteristics of the
CRC patients are summarized in Table 1.
Biochemical analyses
The plasma concentration of CEA and CA19-9 was
measured by using the Roche High-sensitivity Assay kit
performed on a Cobas e601 System. The cut-off point of
CEA is 5 ng/ml and the detection limit is 0.2 ng/ml with
a CV of < 5 %. The cut-off point of CA19-9 is 27 U/ml
and the detection limit is 0.6 U/ml with a CV of < 5 %.
Samples were randomized for testing and blinded to the
trained clinical laboratory technician who analyzed and
interpreted the data.
MicroRNA isolation
MicroRNA was isolated from 200 μl plasma samples using
the miRcute miRNA extraction kit (TIANGEN) according
to the manufacturer’s instructions. A synthetic microRNA
cel-miR-39 (QIAGEN) was added to each plasma speci-
men at a final concentration of 5 nmol/ml as a reference
before isolation. The purified microRNAs were dissolved
in 30 μl RNase-free water (PROMEGA) at a concentration
ranging from 5–50 ng/μl. The ratio of OD260 and OD280
absorbance of each sample was between 1.8 and 2.1. All
Fang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:86 Page 2 of 10
isolated microRNAs were aliquoted and stored at a −80 °C
freezer until use.
cDNA synthesis
Reverse transcription (RT) was carried out in 20 μl solu-
tion that contained 0.2 μl 200 U/μl MMLV reverse tran-
scriptase (PROMEGA), 0.2 μl 40 U/μl ribonuclease
inhibitor (TAKARA), 0.8 μl 10 mmol/ml dNTP mix
(TAKARA), 1.2 μl 10 mmol/ml stem-loop RT primer
(SANGON), 4 μl MMLV RT buffer (PROMEGA), 11.6 μl
RNAase-free water (PROMEGA), and 2 μl microRNA
template. After being mixed gently, the reaction mixtures
were incubated at 25 °C for 5 min, 40 °C for 60 min and
then 70 °C for 15 min. The final cDNA products were
stored at −20 °C until use. The reverse transcription
primers are miR-24 [GenBank: AF480527.1], 5′-GT
CGTATCCAGTGCGTGTCGTGGAGTCGGCAATTG
CACTGATACGACCTGTTCCT-3′; miR-320a [GenBa-nk:
JA682606.1], 5′-GTCGTATCCAGTGCGTGTCGTGGAG
TCGGCAATTGCACTGGATACGACTCGCCCTC-3′;
miR-423-5p [GenBank: JA830813.1], 5′-GTCGTATC
CAGTGCGTGTCGTGGAGTCGGCAATTGCACTG
GATACGACAAAGTCTC-3′; cel-miR-39 [GenBank:
AJ487564.1], 5′-GTCGTATCCAGTGCGTGTCGTGGA
GTCGGCAATTGCACTGGATACGACCAAGCTGA-3′.
Quantitative real-time PCR
Real-time PCR was carried out following the manufac-
turer’s protocol of SYBR Premix Ex Taq TM II reagents
(TAKARA) with 2 μl cDNA template. The PCR mixture
(18 μl) contains 10 μl SYBR mix (TAKARA), 0.4 μl ROX
Reference Dye II (TAKARA), 0.4 μl 10 mmol/ml forward
primer (SANGON), 0.4 μl 10 mmol/ml reverse primer
(SANGON) and 6.8 μl RNAase-free water (PROMEGA).
PCR reaction was performed in duplicates. No-template
PCR was used as a negative control. All real-time PCR
reactions were carried out on an ABI7500 (ABI) machine.
Reaction conditions were 95 °C for 30 s, followed by
40 cycles of 95 °C for 5 s and 60 °C for 34 s. The
primers are: miR-24, 5′-GCAATGTGGCTCAGTTCA
G-3′ (forward), 5′-CAGTGCGTGTCGTGGAGT-3′(reverse);
miR-320a, 5′-AGGGCTAAAAGCTGGGTTGA-3′ (forward),
5′-CAGTGCGTGTCGTGGAGT-3′ (reverse); miR-423-5p,
5′-GCCTGAGGGGCAGAGAGC-3′ (forward), 5′-CC
ACGTGTCGTGGAGTC-3′ (reverse); cel-miR-39, 5′-CAG
AGTCACCGGGTGTAAAT-3′ (forward), 5′-CCAGTGCG
TGTCGTGGAGTC-3′ (reverse).
Statistical analyses
Relative levels of the three microRNAs were quantified
using the 2-ΔΔCq method. The data then were trans-
formed to log10 for analyses. The nonparametric Mann–
Whitney U test and Kruskal–Wallis tests were used to
analyze the abundance of miR-24, miR-320a and miR-
423-5p in the disease and health groups. ROC curves
were applied to analysis the diagnostic values of the
three microRNAs. Youden index (sensitivity + specifi-
city-1) was chosen to identify the optimal cut-off thresh-
old values. Data were analyzed using two-side test and a
P value < 0.05 was considered statistically significant.
The statistical analyses were carried out with the IBM
SPSS 19.0 software and the graphs were generated by
using Graphpad Prism 5.0 and Canvas X.
Results
Establishing quantitative RT-PCR analyses for detecting
miR-24, miR-320a, miR-423-5p and cel-miR-39 in plasma
Since abnormal expression of microRNAs are often associ-
ated with cancer progression, we identified the three micro-
RNAs based on the following (1) up-regulated or down-
regulated in CRC compared with adjacent tissues in the
miRCancer database (http://mircancer.ecu.edu/search.jsp),
or our previous study; (2) has not been analyzed in CRC
patients plasma; and (3) Ct value in plasma is less than 35.
A panel of 7 candidate microRNAs were selected for fur-
ther analysis. For the training set, plasma samples of CRCs
and healthy controls were randomly selected for qRT-PCR
Table 1 Clinicopathological characteristics of 111 CRC patients
Variables n(%)
Gender
Male 59(53.2 %)
Female 52(46.8 %)
Age(median, SD) 60 (14.23)
Location
Rectun 54(48.6 %)
Colon 57(51.4 %)
T category
T1 3(2.7 %)
T2 9(8.1 %)
T3 13(11.7 %)
T4 72 (64.9 %)
Unknown 14(12.6 %)
N category
N0 55(49.6 %)
N1 42(37.8 %)
Unknown 14(12.6 %)
M category
M0 89(80.2 %)
M1 22(19.8 %)
Tumor grade
Stage I + II 54(48.7 %)
Stage III + IV 57(51.3 %)
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analyses. Among them, miR-24, miR-320a, and miR-423-5p
were significantly down-regulated in CRC and were se-
lected for the analyses hereafter.
The specific amplification and stability of the three can-
didate microRNAs in plasma was confirmed in Additional
file 1. Melting curve analyses showed that there was only
one unique peak for every sample (Additional file 1: Figure
S1A-D). Agarose gel electrophoresis also showed one sin-
gle band from randomly selected samples (Additional file
1: Figure S1E). The calculated slopes and coefficient of de-
termination for miR-24 were −2.3815, r2 = 0.9992; miR-
320a were −2.2526, r2 = 0.9974; miR-423-5p were −2.2247,
r2 = 0.9964; and cel-miR-39 were −2.3732, r2 = 0.9998
(Additional file 1: Figure S1F), indicating that the amplifi-
cation efficiencies for miR-24, miR-320a, miR-423-5p, and
cel-miR-39 reached 98.15 %, 106.12 %, 107.89 %, and
98.59 %, respectively. Incubation of the samples at 37 °C
for up to 24 h or repeating freeze-and-thaw did not cause
significant changes in Cq value (Additional file 1: Figure
S2), indicating that the microRNAs were stable in the
plasma. Moreover, intra-assay variations and internal-assay
variations were all less than 2 %, indicating that the RT-
qPCR analyses were accurate and reliable (Additional file
1: Table S1 and S2). This warrants the RT-qPCR analyses
of plasma miRNA for clinical applications.
CRC patients have reduced abundances of miR-24,
miR-320a, and miR-423-5p in the plasma
To determine whether the plasma levels of miR-24, miR-
320a, and miR-423-5p were changed in CRC patients,
real-time RT-PCR was carried out to assess plasma con-
centrations of the three microRNAs in healthy controls
and CRC patients. Compared with healthy controls, the
abundances of all three microRNAs in the plasma were
reduced in patients with CRC and benign lesions (colorec-
tal adenoma and polyps), but increased in patients with
IBD (Fig. 1). The expression levels of miR-320a and miR-
423-5p were inversely correlated with the progression
stages of the disease from normal-benign lesions-
carcinoma. In addition, the plasma level of miR-320a and
miR-423-5p was higher in patients with rectal cancer
than those with CRC (Additional file 1: Figure S3A-
C). No difference was found between patients with
adenoma and polyps, as well as the patients with
Crohn’s disease (CD) and with ulcerative colitis (UC)
(Additional file 1: Figure S3D-I).
The plasma levels of miR-24, miR-320a and miR-423-5p
have diagnosis values for CRC
To determine whether the plasma levels of miR-24, miR-
320a, and miR-423-5p had CRC diagnostic values, the
ROC curve was applied to analyze their diagnostic
sensitivity and specificity (Fig. 2; Table 2). At the
threshold of −1.731, the optimal sensitivity and specificity
of miR-24 were 78.38 % and 83.85 % in distinguishing
CRC from normal controls [area under curve (AUC) =
0.839]. At the threshold of −1.006, the sensitivity and spe-
cificity of miR-320a were 92.79 % and 73.08 % (AUC=
0.886). At the threshold of −0.854 (AUC= 0.833), and the
sensitivity and specificity of miR-423-5p were 91.89 % and
70.77 %. Combined analyses of three microRNAs showed
a higher AUC (0.899) and sensitivity (92.79 %) but with
lower specificity (70.77 %) in distinguishing CRC patients
and normal control. In order to determine whether the
plasma level of the three microRNA had clinical values for
CRC diagnosis, the PPV (positive predictive value), NPV
(negative predictive value), and diagnosis efficiency were
calculated. As shown in Table 2, the PPV for the three
microRNAs were higher than 72 %. The results indicate
that a person with high plasma levels of any one of the
three microRNAs has a greater risk of CRC than those
with low plasma levels of the three microRNAs. Addition-
ally, the NPV and diagnosis efficiency of the three micro-
RNAs were all higher than 80 %. The results indicate that
the plasma levels of the three microRNAs have high diag-
nosis values.
Fig. 1 Plasma levels of miR-24, miR-320a, and miR-423-5p are reduced in patients with CRC. The relative levels of miR-24 (a), miR-320a (b) and
miR-423-5p (c) in patients with benign lesions, CRC, IBD, and healthy controls. Numbers are normalized to the reference of cel-miR-39 and shown
as log10. The Wilcoxon two-sample tests were performed to examine the difference of three microRNAs between normal controls and colorectal
disease groups. (*, p < 0.05; **, p< 0.01; and *** p < 0.001)
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The AUC of miR-24 for distinguishing CRC and IBD
was 0.9742 (95 % CI: 0.9513-0.9971) based on the opti-
mal cut-off (−0.4363) according to Youden Index. The
sensitivity and specificity was 91.89 % and 100 %, re-
spectively. The AUC of miR-320a for distinguishing
CRC and IBD was 0.9901(95 % CI: 0.9791-1.001). The
sensitivity and specificity were 92.79 % and 100 % (cut-
off: −1.025). At a threshold of −0.8093, the sensitivity
and specificity of miR-423-5p were 91.89 % and 100 %.
The plasma level of miR-24, miR-320a and miR-423-5p
can be used for early detection of CRC
Early diagnosis and treatment of CRC is of great values
to improve survival of CRC patients. Currently, CEA
and CA19-9 are two most commonly used diagnosis
markers for CRC. Therefore, the performance of the
three microRNAs and CEA or CA19-9 in detecting early
stages (stage I, stage II) of CRC was compared. In 54 pa-
tients with CRC at early stages, both CEA and CA19-9
were detected in 11 patients and the sensitivity was
20.37 %. In contrast, the plasma miR-24, miR-320a and
miR-423-5p were detected in 42 (77.78 %), 49 (90.74 %),
and 48 (88.89 %) patients, respectively (Fig. 3). Accord-
ing to the ROC curve, the AUC of three microRNAs
reached 0.822, 0.897, and 0.839, respectively (Fig. 4a-c).
By combining with the three microRNAs, the sensitivity
was increased to 90.74 %, but the specificity dropped to
70.77 % (AUC = 0.941) (Fig. 4d, Table 3). Although the
specificity of the three microRNAs was similar to CEA
and CA19-9, the diagnosis efficiency and NPV, especially
the sensitivity of the three microRNAs were higher than
those of CEA and CA19-9. The findings validate the per-
formance of miR-24, miR-320a, and miR-423-5p as a
plasma marker for early detection of CRC, and indicate
Table 2 The diagnosis value between CRC and normal controls
Variables miR-24 miR-
320a
miR-423-
5p
CEA CA19-9
Cut-off −1.731 −1.006 −0.854 5 ng/
ml
27U/ml
Sensitivity 78.38 % 92.79 % 91.89 % 40.54 % 36.04 %
Specificity 83.85 % 73.08 % 70.77 % 95.38 % 93.08 %
PPV 80.56 % 74.64 % 72.86 % 88.24 % 81.63 %
NPV 81.95 % 92.23 % 82.88 % 65.26 % 63.02 %
Diagnosis
efficiency
81.33 % 82.16 % 80.50 % 70.12 % 66.80 %
PPV positive predictive value, NPV negative predictive value
Fig. 2 ROC curve analyses demonstrating that plasma levels of miR-24, miR-320a, and miR-423-5p are different among patients with CRC, benign
lesions, and healthy controls. (a-c), ROC curves showing plasma levels of miR-24, miR-320a, and miR-423-5p in CRC patients are different from
healthy controls. (d), Combination ROC curve analyses of the three microRNAs between CRC patients and healthy controls
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that the three microRNAs are better biomarkers for
CRC early detection than CEA and CA19-9.
The changes in plasma level of miR-24, miR-320a and
miR-423-5p after the surgery predicts the risk of
post-surgery metastasis
To determine whether the plasma levels of the three
microRNAs had predicting values for clinical im-
provement after the surgery, the plasma levels of the
three microRNAs in 43 patients were compared be-
fore and after the surgery. The data showed that the
plasma levels of miR-24, miR-320a, and miR-423-5p
in 37 (37/43 = 86.05 %), 35 (35/43 = 81.40 %), and 36
(36/43 = 83.72 %) patients, respectively, were increased
after the surgery. The rest of the patients showed re-
duced plasma level of the three microRNAs after the
surgery (Fig. 5). In the follow-up studies, it was found
that the patients with reduced plasma level of the
three microRNAs had high risk of liver metastasis
(miR-24: 1/6 = 16.67 %; miR-320a, 1/8 = 12.50 %; miR-
423-5p, 1/7 = 14.29 %) within six months later after
the surgery. In contrast, the patients with increased
plasma level of the three microRNAs had low risk of
metastasis (miR-24: 1/31 = 3.2 %; miR-320a, 1/29 =
3.4 %; miR-423-5p, 1/30 = 3.3 %). Together, the data
indicate that changes in plasma level of the three
microRNAs after the surgery has prediction values for
postoperative metastasis.
Fig. 3 Plasma levels of miR-24, miR-320a, miR-423-5p are better biomarkers for early detection of CRC than currently used CEA, CA19-9. a-f
Two-parameter classification is used to detect early stages of CRC. The cut-off value 5.0 ng/mL for CEA is, and 27U/ mL for CA19-9. The data is
presented as log2. The cut-off values for miR-24, miR-320a and miR-423-5p are −1.731, −1.006, and −0.854, respectively. The data is calculated
from the ROC curve. (g), Detection rates of the three microRNAs CEA, and CA19-9 in a total of 54 patients with early stages of CRC
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Discussion
About 52.5 % microRNA coding sequences are located at
fragile sites and genomic regions [24], and are more vul-
nerable to mutations or environmental influences. Aber-
rant microRNA expression and mutations have been
shown to contribute to cancer initiation and progression
[25–28], which can be potential biomarkers for cancer
diagnosis and progression. Assessing microRNA expres-
sions in CRC requires invasive examination, which limits
the values of using microRNA as biomarkers for CRC
diagnosis and prognosis. In our previous experiments,
normal colorectal cells (CCD-18Co) have a higher expres-
sion than CRC cells (LS 174 T, HCT-8, SW480 and
SW620) (Additional file 1: Figure S4). Herein, we report
that expression of miR-24, miR-320a and miR-423-5p in
the plasma of CRC patients was reduced and that changes
of plasma levels of miR-24, miR-320a and miR-423-5p
predicted the risk of post-surgery metastasis of CRC pa-
tients. The results indicate that the plasma level of miR-
24, miR-320a and miR-423-5p can serve as normal bio-
markers for CRC diagnosis and prognosis.
MiR-24 is a master regulator from the gene cluster of
miR-23a–27a–24-2. Its expression is frequently down-
regulated in a variety of cancers [18, 29–32], includ-
ing CRC. It has been shown that miR-24 can function
as a tumor suppressor in CRC, including suppressing
proliferation, migration, and invation [18]. Moreover,
miR-24 elicits its tumor suppression activity by
repressing DHFR expression in CRC cells. MiR-320 is
also a tumor suppressor. Expression of miR-320 is
down-regulated in many human malignancies [33–35].
Overexpression of miR-320 inhibit colon cell prolifer-
ation, migration, and invasion. Moreover,miR-320 reg-
ulates the Wnt/β-catenin pathway partly by targeting
FOXM1 that promotes the tumor initiation and progres-
sion [36]. In addition, miR-423-5p also contributes to pro-
liferation and invasion in gastric cancer by targeting TIF1
Fig. 4 ROC curve analyses for detection of CRC at early stages (I, II). a-c ROC curves for miR-24, miR-320a, and miR-423-5p in 54 patients with early
stages of and 130 healthy controls. d Combination ROC curve analyses of three microRNAs for patients with early stages of CRC and
healthy controls
Table 3 The diagnosis value between early stage of CRC and
normal controls
Variables miR-24 miR-
320a
miR-423-
5p
CEA CA19-9
Cut-off −1.731 −1.006 −0.854 5 ng/
ml
27U/ml
Sensitivity 77.78 % 90.74 % 88.89 % 20.37 % 20.37 %
Specificity 83.85 % 73.08 % 70.77 % 95.38 % 93.08 %
PPV 66.67 % 58.33 % 55.81 % 64.71 % 55 %
NPV 90.08 % 95 % 82.88 % 74.25 % 73.78 %
Diagnosis
efficiency
82.07 % 78.26 % 76.09 % 73.37 % 71.74 %
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[37]. However, the role of miR-423-5p in CRC is largely
unknown.
To our knowledge, this is the first comprehensively
study on the expression and clinical significance of plasma
levels of microRNAs– miR-24, miR-320a, and miR-423-5p
in CRC patients. Reduced plasma level of miR-24 was
detected in 78.38 % patients with CRC, and that for
miR-320a and miR-423-5p were even higher (>90 %).
Moreover, all of the PPV were higher than 70 % and
the diagnosis efficiency was higher than 80 %. Con-
sistently, the AUCs for CEA and CA19-9 were both
lower than three microRNAs whether in the diagnosis
of CRC or early stages of CRC.
Clinical data shows that the 5-year survival rate of
early stage of CRC patients after surgery is higher than
90 %. However, due to no obvious symptoms of early
CRC and the lack of sensitive detection methods for
early diagnosis, the majority of CRC patients are diag-
nosed at the advanced stages and lost their best time for
treatment. Therefore, the low 5-year survival rate of
post-operation is lower than 20 %. The colonoscopy can
only detect 18 %–35 % of early CRC [38–40]. The two
most commonly used biomarkers for CRC are CEA and
CA19-9, which can only detecte 10 % and 15 % 1st stage
CRC, respectively [41]. Therefore, high sensitive bio-
markers for CRC early detection are urgently needed.
Detection of the plasma level of the three microRNAs
significantly improve the detection rate of CRC at early
stages (miR-24: 77.78 %; miR-320a: 90.74 %; miR-423-
5p: 88.89 %). In conclusion, compared with CEA and
CA19-9, the performance of the plasma level of the
three microRNAs indicates that they have great clinical
values for CRC detection.
The plasma levels of miR-24, miR-320a and miR-423-
5p of patients with benign lesions (adenoma and polyps)
were between those in normal controls and CRC pa-
tients. Furthermore, the expression of miR-320a and
miR-423-5p was inversely correlated with the progres-
sion of the disease. This indicates that the plasma level
miR-320a and miR-423-5p can be used to predict the
disease conditions. Unlike patients with benign lesions
(adenoma and polyps), the plasma levels of the three
microRNAs were increased in patients with the IBD.
The finding warrants the promise of using plasma levels
of the three microRNAs as biomarkers for early detec-
tion of CRC, benign colorectal diseases, and IBD. Fur-
thermore, the data also showed that the increased
circulation levels of the three microRNAs were associ-
ated with the outcome of the surgical treatment. This
suggests that the plasma levels of the three microRNAs
are of potential prognosis values for CRC progression
after the surgery.
Conclusions
In summary, the plasma levels of miR-24, miR-320a, and
miR-423-5p were reduced in patients with CRC and re-
versely correlated with the stages of progression. Fur-
thermore, the changes of plasma level of the three
microRNAs predicted the risk of post-surgery metasta-
sis. The results suggest that the plasma level of miR-24,
miR-320a, and miR-423-5p can serve as novel bio-
markers for CRC diagnosis and prognosis.
Additional file
Additional file 1: Figure S1. Validation of the RT-qPCR analyses for
cel-miR39, miR-24, miR-320a and miR-423-5p. Dissociation curves of
miR-24 (A), miR-320a (B), miR-423-5p (C) and cel-miR-39 (D) were shown.
(E), 2 % agarose gel electrophoresis of RT-qPCR production from
randomly selected 2 plasma samples (M presents marker; 1, 2, 3, 4
present the product of miR-24, miR-320a, miR-423-5p and cel-miR-39,
respectively, and B means blank control). (F), the calibration curves of
miR-24, miR-320a, miR-423-5p and cel-miR-39, using serious 5 orders of
magnitude dilution of cDNA were shown, and each point presents the
average of duplication. Figure S2. The stability experiments of plasma
miR-24, miR-320a and miR-423-5p. Plasma levels of miR-24, miR-320a,
Fig. 5 The changes of plasma levels of miR-24, miR-320a, and miR-423-5p before (Preoperation) and after surgery (Postoperation). The y-axis indicates
the relative values of miR-24 (a), miR-320a (b) and miR-423-5p (c) which were normalized to cel-miR-39 and shown as log10 (***, p < 0.001, Wilcoxon
matched-paired signed ranks sum test)
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miR-423-5p were stable after prolonged 37 °C temperature incubation
from 1 to 24 hours(A) or at least 5 freeze-thaw cycles(B). Table S1.
Analysis of intra-assay variations. Table S2. Analysis of inter-assay
variations. Figure S3. Plasma level of miR-24, miR-320a and miR-423-5p
in different diseases groups. (A-C), the relative expression of three
microRNAs in normal controls, patients with colon cancer and rectal cancer;
(D-F), the relative level of three microRNAs in normal controls, patients with
adenoma and polyps; (G-I), the relative abundance of three microRNAs in
normal controls, patients with CD and UC; The Wilcoxon two-sample tests
were performed to examine the difference of three microRNAs between
each group. (**, p<0.01; ***, p<0.001; ns, non-significance). Figure S4.
Relative expression of three candidate microRNAs in 4 CRC cell lines and
1 normal colorectal cell line. The relative quantification of miR-24 (A),
miR-320a (B) and miR-423-5p (C) was standardized to reference gene
U6. The bar chat was represented by mean ±SD (*, p<0.05).
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